Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
A 47-Year-Old Woman with Tension-Type Headaches
JAMA 286:960-966, Welch,K.M.A., 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Clinical and Genetic Aspects of Distal Myopathies
Muscle Nerve 24:1440-1450, Saperstein,D.S.,et al, 2001
Transient Ischemic Attack and Stroke Associated with Sildenafil (Viagra) Use
Neurol 57:1730-1731, Morgan,J.C.,et al, 2001
Eosinophilic Fasciitis and Simvastatin
Arch Int Med 161:1456-1457, Choquet-Kastylevsky,G.,et al, 2001
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Dermatomyositis
Lancet 355:53-57, Callen,J.P., 2000
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Cholesterol and Strokes
BMJ 320:459-460, Oliver,M.F., 2000
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Desmin Myopathy, a Skeletal Myopathy with Cardiomyopathy Caused by Mutations in the Desmin Gene
NEJM 342:770-780, Dalakas,M.C.,et al, 2000
Depression in Parkinson's Disease
BMJ 320:1287-1288, Allain,H.,et al, 2000
Pyridostigmine-Induced Microcephaly
Neurol 54:1873-1874, Niesen,C.E.&Shah,N.S., 2000
The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Prevention of Radiographic-Contrast-Agent-Induced Reductions In Renal Function by Acetylcysteine
NEJM 343:180-184,210, Tepel,J. et al, 2000
Pravastatin Therapy and The Risk of Stroke
NEJM 343:317-326, White,H.D. et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Incidence and Prevalence of Neurological Disorders Associated with HIV Since the Introduction of Highly Active Antiretroviral Therapy (HAART)
JNNP 69:376-380, Maschke,M. et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Antioxidant Therapy in Neurologic Disease
Arch Neurol 57:1265-1270, Delanty,N. & Dichter,M.A., 2000
Vitamin E and Beta Carotene Supplementation in High Risk for Stroke
Arch Neurol 57:1503-1509, Leppala,J.M.,et al, 2000
Statins and the Risk of Dementia
Lancet 356:1627-1631, Jick,H.,et al, 2000
AIDS-Related Focal Brain Lesions in the Era of Highly Active Antiretroviral Therapy
Neurol 55:1194-1200, Ammassari,A.,et al, 2000
Intake of Flavonoids, Carotenoids,Vitamins C and E, and Risk of Stroke in Male Smokers
Stroke 31:2301-2306, Hirvonen,T.,et al, 2000
Acetazolamide Treatment for Migraine Aura Status
Neurol 55:1588-1589, Haan,J.,et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
An Overview of Acute Stroke Therapy
Arch Int Med 160:3196-3206, Fisher,M. & Schaebitz,W., 2000
Prevention of Ischaemic Stroke
BMJ 321:1455-1459, Gubitz,G. & Sandercock,P., 2000
Efficacy of Rivastigmine in Dementia with Lewy Bodies: a Randomised, Double-blind, Placebo-controlled International Study
Lancet, 356:2031-2036,2024, McKeith,I.,et al, 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000
N-Acetylcysteine Therapy for Unverricht-Lundborg Disease
Neurol 52:426-427, Selwa,L.M., 1999
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Prevention of a First Stroke,A Review of Guidelines and a Multidisciplinary Consensus Statement from the National Stroke Association
JAMA 281:1112-1120,1146, Gorelick,P.B.,et al, 1999
Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
Neurol 52:1138-1145,1115, Neumann,P,J.,et al, 1999
Myocardial Injury and Left Ventricular Performance After Subarachnoid Hemorrhage
Stroke 30:780-786, Mayer,S.A.,et al, 1999
Muscle Pain after Exercise
Lancet 353:1062, Nielen,C.&Mazzone,P., 1999
Phenotypic Variability in Rippling Muscle Disease
Neurol 52:1453-1459, Vorgerd,M.,et al, 1999
Relation of Consumption of Vitamin E, Vitamin C, and Carotenoids to Risk for Stroke among Men in the United States
Ann Int Med 130:963-970, Ascherio,A.,et al, 1999
Randomized Trial of Sildenafil for the Treatment of Erectile Dysfunction in Spinal Cord Injury
Ann Neurol 46:15-21, Giuliano,F.,et al, 1999
Amyloid Myopathy:An Underdiagnosed Entity
Ann Neurol 43:719-728, Spuler,S.,et al, 1999
Effect of Aldose Reductase Inhibition on Nerve Conduction and Morphomedtry in Diabetic Neuropathy
Neurol 53:580-591, Greene,D.A.,et al, 1999